Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Hinge Health (HNGE) Preferred Stock Liabilities (2023 - 2026)

Hinge Health's Preferred Stock Liabilities history spans 3 years, with the latest figure at $199.9 million for Q4 2025.

  • On a quarterly basis, Preferred Stock Liabilities fell 76.52% to $199.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $199.9 million, a 76.52% decrease, with the full-year FY2025 number at $199.9 million, down 76.52% from a year prior.
  • Preferred Stock Liabilities hit $199.9 million in Q4 2025 for Hinge Health, roughly flat from $199.9 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for HNGE hit a ceiling of $851.3 million in Q4 2023 and a floor of $199.9 million in Q2 2025.
  • Historically, Preferred Stock Liabilities has averaged $572.1 million across 3 years, with a median of $851.3 million in 2023.
  • Biggest five-year swings in Preferred Stock Liabilities: changed 0.0% in 2024 and later plummeted 76.52% in 2025.
  • Tracing HNGE's Preferred Stock Liabilities over 3 years: stood at $851.3 million in 2023, then changed by 0.0% to $851.3 million in 2024, then plummeted by 76.52% to $199.9 million in 2025.
  • Business Quant data shows Preferred Stock Liabilities for HNGE at $199.9 million in Q4 2025, $199.9 million in Q3 2025, and $199.9 million in Q2 2025.